PDE9 Inhibitor
Heart Failure (HFrEF and HFpEF)
ClinicalActive
Key Facts
About Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a private, clinical-stage biotech company pioneering novel treatments for cardiovascular disease, which remains the leading cause of death in the US. The company's pipeline is built on two groundbreaking, first-in-class mechanisms: a PDE9 inhibitor for heart failure and the first-ever CaMKII inhibitor in clinical development for rare arrhythmias and broader indications like heart failure and atrial fibrillation. Backed by a seasoned team of physician-scientists and industry veterans, and supported by a significant investment from Bain Capital Life Sciences, Cardurion is positioned to address significant unmet needs across the cardiovascular therapeutic landscape.
View full company profile